ArticleAdvanced pharmaceutical bulletin2017

siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells.

Saiedeh Razi Soofiyani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.